Study of genes in people with pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This study looks at genetic (inherited) factors related to pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF). It may help researchers understand why some families are more affected and could guide future testing or treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have a family member who has been diagnosed with IPF
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the symptoms and patterns of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. By joining, you help doctors better understand the disease, which may lead to better care.
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This study follows people with idiopathic pulmonary fibrosis (IPF) to learn how traditional Chinese medicine may help. By joining, you help researchers understand better ways to manage this lung condition.
This study looks at genetic differences in people with idiopathic pulmonary fibrosis (a lung scarring condition with no known cause). It may help researchers understand what influences the disease and guide future treatment options.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.